James D. Neaton, PhD

Professor, Division of Biostatistics

James D. Neaton

Contact Info

neato001@umn.edu

Office Phone 612-626-9040

Office Address:
2221 University Ave. SE, Room 200
Minneapolis, MN 55455

PhD, Biometry, University of Minnesota, 1984

MS, Biometry, University of Minnesota, 1970

BA, Biometry, University of Minnesota, 1969

Summary

I lead a large network called INSIGHT that conducts international trials of HIV and influenza treatments and conducts observational studies of C. difficile infection and influenza.

I also lead research on Ebola in West Africa, that includes clinical trials of vaccines and treatments, and a large cohort study of Ebola survivors and their close contacts.

I am Principal Investigator of a training program funded by NHLBI, NIH to train predoctoral students in clinical trials.

Expertise

Chronic diseases, infectious disease, methods, international research, clinical trials, clinical research, HIV/AIDS

Awards & Recognition

  • Delta Omega Honorary Public Health Society
  • Pi Mu Epsilon

Professional Associations

  • Society for Clinical Trials (President, 2006–2007)
  • Biometric Society
  • American Statistical Association
  • American Heart Association Council on Epidemiology
  • International AIDS Society

Research

Research Funding Grants

  • 2015–2018, NIH Nat'l Inst of Allergy & Infect Dis, "International Network for Strategic Initiatives in Global HIV Trials (INSIGHT): START," Principal Investigator
  • 2016–2017, Leidos Biomedical Research, Inc., "PREVAIL IV (Q5) Double-Blind Randomized Two-Phase Placebo Controlled Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus and Safety in Male Ebola Survivors with Evidence of Ebola Virus Persistence in Semen," Principal Investigator
  • 2016–2021, NIH Nat'l Heart, Lung, and Blood Inst., "Training in Biostatistics for Heart, Lung, and Blood Disease Research," Principal Investigator
  • 2015–2017, Leidos Biomedical Research, Inc., "PREVAC: Partnership for Research on Ebola Vaccines in Liberia, Guinea and Sierra Leone," Principal Investigator
  • 2015–2018, Leidos Biomedical Research, Inc., "Anti-Influenza Hyperimmune Intravenous Immunoglobulin (FLU - IVIG) Internationa," Principal Investigator
  • 2015–2020, Leidos Biomedical Research, Inc., "Flu Study (FLU 003+ 004)," Principal Investigator
  • 2015–2020, Leidos Biomedical Research, Inc., "Clinical Research Management Operations Center for Ebola Virus Disease - PREVAIL III (Survivor/Natural History)," Principal Investigator
  • 2015–2017, Leidos Biomedical Research, Inc., "Data Management and Biostatistical Services in Support of the MCM RCT Protocol - PREVAIL II (MCM)," Principal Investigator
  • 2015–2017, Leidos Biomedical Research, Inc., "Clinical Research Management Operations Center for Ebola Virus Disease - PREVAIL I (Vaccine)," Principal Investigator
  • 2015–2020, Leidos Biomedical Research, Inc., "Ebola Master Agreement / BOA 16X054," Principal Investigator
  • 2014–2017, Merck and Co Inc., "Outcomes of Post-transplant Patients Treated for C. Difficile Infections," Principal Investigator
  • 2014–2017, Minneapolis Medical Research Foundation, "Treatment to Reduce Inflammation and Improve Immune Recovery Among Older HIV Patients," Project Principal Investigator
  • 2013–2020, Leidos Biomedical Research, Inc., "Flu Study (FLU 002)," Principal Investigator
  • 2013–2018, Leidos Biomedical Research, Inc., "Master: Flu Study, Principal Investigator

Publications

Teaching

Courses

  • PubH 7420, Clinical Trials: Design, Implementation, and Analysis

Community Engagement

I have served on several national committees and advisory panels including the U.S. Public Health Service Panel on Clinical Practices for the Treatment of HIV Infection, the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee, and the National Academy of Sciences, Committee on National Statistics Oversight Committee for Workshop on Handling Missing Data in Clinical Trials.

Media

Video

In The News

In the Media

  • Amid Crisis, Ebola Drug Narrowly Missed Threshold to Prove Effectiveness (STAT)
  • U of M Research Confirms Benefits of Early HIV Treatment (MPR)

SPH News